S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
NASDAQ:BNR

Burning Rock Biotech (BNR) Stock Price, News & Analysis

$0.81
-0.04 (-4.72%)
(As of 03/1/2024 ET)
Today's Range
$0.81
$0.90
50-Day Range
$0.72
$0.97
52-Week Range
$0.69
$3.54
Volume
151,174 shs
Average Volume
55,893 shs
Market Capitalization
$82.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BNR stock logo

About Burning Rock Biotech Stock (NASDAQ:BNR)

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

BNR Stock Price History

BNR Stock News Headlines

Burning Rock Biotech Ltd. ADR
Burning Rock Biotech Ltd (BNR)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Burning Rock Biotech Ltd ADR
Q3 2023 Burning Rock Biotech Ltd Earnings Call
Burning Rock Reports Third Quarter 2023 Financial Results
Q2 2023 Burning Rock Biotech Ltd Earnings Call
Burning Rock Biotech Q2 Loss Narrows
See More Headlines
Receive BNR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Burning Rock Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2021
Today
3/02/2024
Next Earnings (Estimated)
3/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:BNR
Fax
N/A
Employees
1,138
Year Founded
N/A

Profitability

Net Income
$-140,820,000.00
Net Margins
-127.05%
Pretax Margin
-122.10%

Debt

Sales & Book Value

Annual Sales
$81.66 million
Book Value
$1.64 per share

Miscellaneous

Free Float
71,542,000
Market Cap
$82.94 million
Optionable
Not Optionable
Beta
0.25
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report














BNR Stock Analysis - Frequently Asked Questions

How have BNR shares performed in 2024?

Burning Rock Biotech's stock was trading at $0.93 at the start of the year. Since then, BNR shares have decreased by 13.1% and is now trading at $0.8081.
View the best growth stocks for 2024 here
.

Are investors shorting Burning Rock Biotech?

Burning Rock Biotech saw a decrease in short interest during the month of February. As of February 15th, there was short interest totaling 401,600 shares, a decrease of 8.1% from the January 31st total of 437,000 shares. Based on an average daily volume of 74,300 shares, the short-interest ratio is currently 5.4 days. Currently, 0.5% of the company's stock are short sold.
View Burning Rock Biotech's Short Interest
.

When is Burning Rock Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our BNR earnings forecast
.

How were Burning Rock Biotech's earnings last quarter?

Burning Rock Biotech Limited (NASDAQ:BNR) issued its quarterly earnings data on Tuesday, November, 16th. The company reported ($1.64) EPS for the quarter, missing the consensus estimate of ($1.61) by $0.03. The company earned $19.65 million during the quarter. Burning Rock Biotech had a negative net margin of 127.05% and a negative trailing twelve-month return on equity of 70.22%. During the same period in the prior year, the firm earned ($0.18) earnings per share.

What other stocks do shareholders of Burning Rock Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Burning Rock Biotech investors own include Tiziana Life Sciences (TLSA), Teck Resources (TECK), Herman Miller (MLHR) and Immunic (IMUX).

When did Burning Rock Biotech IPO?

(BNR) raised $196 million in an initial public offering on Friday, June 12th 2020. The company issued 13,500,000 shares at $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen acted as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.

Who are Burning Rock Biotech's major shareholders?

Burning Rock Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Kynam Capital Management LP (8.47%), Massachusetts Financial Services Co. MA (3.94%) and Redwood Wealth Management Group LLC (0.11%).

How do I buy shares of Burning Rock Biotech?

Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BNR) was last updated on 3/3/2024 by MarketBeat.com Staff